Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 11Gynecologic 5Thoracic 4Gastrointestinal 4Genitourinary 3Endocrine 3Dermatologic 3Breast 3Sarcoma 2Other solid neoplasm 2NET 1Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 11Adrenocortical Carcinoma 7Thyroid Carcinoma, Anaplastic 5Carcinoma, Neuroendocrine 4Thyroid Neoplasms 3Adrenal Cortex Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Carcinoma, Small Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Pathologic Processes 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma 1Neoplasms, Unknown Primary 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 10Paclitaxel 7Iodine-131 6Fluorodeoxyglucose F18 6Sorafenib 5vandetanib 4trametinib 4selpercatinib 4dabrafenib 4pembrolizumab 3fosbretabulin 3cabozantinib 3Vemurafenib 3Sunitinib 3Specimen Handling 3Nivolumab 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2romidepsin 2pazopanib 2lenvatinib 2combretastatin 2Trastuzumab 2Thyrotropin Alfa 2Ipilimumab 2Gefitinib 2FAPI-46 2Everolimus 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Thyroid Neoplasms × pembrolizumab × Endocrine × Clear all
NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
25 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03012620 2024-02-28

AcSé

UNICANCER

Phase 2 Completed
334 enrolled
CNSEndocrineGynecologicHead & NeckLymphoidSarcoma

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡